1. Home
  2. PODD vs HOLX Comparison

PODD vs HOLX Comparison

Compare PODD & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Insulet Corporation

PODD

Insulet Corporation

HOLD

Current Price

$239.59

Market Cap

17.0B

Sector

Health Care

ML Signal

HOLD

Logo Hologic Inc.

HOLX

Hologic Inc.

HOLD

Current Price

$75.64

Market Cap

16.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PODD
HOLX
Founded
2000
1985
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medical Electronics
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.0B
16.6B
IPO Year
2007
1995

Fundamental Metrics

Financial Performance
Metric
PODD
HOLX
Price
$239.59
$75.64
Analyst Decision
Strong Buy
Hold
Analyst Count
20
13
Target Price
$358.00
$77.89
AVG Volume (30 Days)
1.0M
2.1M
Earning Date
05-20-2026
04-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
3.48
0.79
Revenue
$2,708,100,000.00
$4,100,500,000.00
Revenue This Year
$24.33
$4.74
Revenue Next Year
$19.33
$5.03
P/E Ratio
$70.10
$95.77
Revenue Growth
30.73
1.74
52 Week Low
$230.08
$51.90
52 Week High
$354.88
$75.69

Technical Indicators

Market Signals
Indicator
PODD
HOLX
Relative Strength Index (RSI) 37.81 65.62
Support Level $238.68 $74.53
Resistance Level $299.75 N/A
Average True Range (ATR) 8.49 0.22
MACD 0.71 0.03
Stochastic Oscillator 7.18 90.79

Price Performance

Historical Comparison
PODD
HOLX

About PODD Insulet Corporation

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.

About HOLX Hologic Inc.

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

Share on Social Networks: